Page 47 - Noble-Virtual-Healthcare-2024

Theravance Biopharma, Inc.

SELECTED FINANCIAL ITEMS TBPH

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue 10.42 13.75 15.69 17.57 57.42
Gross Profit (4.16) 4.32 7.38 9.25 16.80
Gross Margin -40% 31% 47% 53% 29%
EBIT (23.34) (14.95) (8.76) (6.24) (53.29)
EBIT Margin -224% -109% -56% -36% -93%
Net Income to Common Shareholders (22.09) (15.65) (8.95) (8.51) (55.19)
Net Margin -212% -114% -57% -48% -96%

Balance Sheet Key Items
Total Assets 538.55 446.63 413.59 382.00 382.00
Cash & Short Term Investments 187.67 105.60 71.69 39.55 39.55
% of Assets 35% 24% 17% 10% 10%
Current Assets -Total 261.34 192.00 161.69 133.54 133.54
% of Assets 49% 43% 39% 35% 35%
Total Liabilities 167.99 166.47 167.46 169.00 169.00
% of Assets 31% 37% 40% 44% 44%
Current Liabilities - Total 26.18 24.55 25.37 24.77 24.77
% of Assets 5% 5% 6% 6% 6%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 370.56 280.16 246.13 213.00 213.00
% of Assets 69% 63% 60% 56% 56%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (11.22) (12.44) (2.49) (0.85) (27.00)
Net Cash Flow - Investing (43.05) 11.05 (0.02) (0.68) (32.70)
Net Cash Flow - Financing (56.24) (80.68) (31.40) (30.61) (198.93)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference